Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients who achieve PR at IRA will receive mosunetuzumab with lenalidomide augmentation during C5-8. Primary response assessment (PRA) will occur after C8. Patients who remain in PR at PRA will continue for additional 4 cycles (extended augmentation).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona diagnoza chłoniaka pęcherzykowego (stopnie 1-3a) lub chłoniaka strefowego
- •Chłoniak musi mieć białko CD20 potwierdzone badaniem mikroskopowym
- •Nigdy wcześniej nie leczone systemowo (z wyjątkiem kortykosteroidów na łagodzenie objawów)
- •Co najmniej jeden widoczny guz w badaniu obrazowym o rozmiarze większym niż 1,5 cm
- •Wymaga rozpoczęcia leczenia systemowego zgodnie z ustalonymi kryteriami medycznymi
- •Gotowość do podpisania zgody na udział w badaniu i przestrzegania jego reguł
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Yale Cancer Center
New Haven, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Lifespan Cancer Insitute
Providence, United States
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.